A practical reference on evidence gap: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
A depsipeptide is a peptide in which one or more amide, -C(O)NHR-, linkages are replaced by the corresponding ester, -C(O)OR-. Depsipeptides usually contain alternating amide and ester linkages. Elimination of an amide linkage in a peptide structure results in a decrease of H-bonding capability, which is responsible for secondary structure within peptides, thus inducing structural warping and diversity. Because of the decreased electron delocalization in esters relative to amides, depsipeptides have lower rotational barriers and therefore are quite flexible and malleable structures. They are mainly produced in nature by soil and marine sediment inhabiting bacteria.
Silencing systemin did not affect the ability of black nightshade to resist herbivory and, when competing against normal plants, silenced plants produced more above-ground biomass and berries. Upon herbivory, systemin was down-regulated in black nightshade in contrast to the other peptides which are up-regulated after herbivory. By contrast HypSys were up-regulated and activated the synthesis of protease inhibitors. The down-regulation of systemin was associated with increased root mass but did not decrease shoot mass, demonstrating that systemin can cause developmental changes as a result of herbivory, allowing the plant to tolerate, rather than directly resist attack. Tomato roots were also affected by tomato systemin, with root growth increasing at high tomato systemin concentrations. By allocating more resources to the roots, plants under attack are thought to store carbon and then use it to re-grow when the attack ends. Overexpressing AtPEP1 also increased root and shoot biomass in A. thaliana.
At 11:07, radar detected another, larger attack. This second wave consisted of 107 aircraft. They were met while still 60 miles (97 km) out, and at least 70 of these aircraft were shot down before reaching the ships. Six attacked Rear Admiral Alfred E. Montgomery's group, nearly hitting two of the carriers and causing casualties on each. Four of the six were shot down. A small group of torpedo aircraft attacked Enterprise, with one torpedo exploding in the wake of the ship. Three other torpedo aircraft attacked the light carrier Princeton and were shot down. In all, 97 of the 107 attacking aircraft were destroyed. A third raid, consisting of 47 aircraft, came in from the north. It was intercepted by 40 fighters at 13:00, while 50 miles (80 km) out from the task force. Seven Japanese aircraft were shot down. A few broke through and made an ineffective attack on Task Group 58.4. Many others did not press home their attacks. This raid therefore suffered less than the others, and 40 of its aircraft managed to return to their carriers. A fourth Japanese raid was launched between 11:00 and 11:30, but pilots had been given an incorrect position for the U.S. fleet and could not locate it. They broke into two loose groups and turned for Guam and Rota to refuel. One group flying toward Rota stumbled upon Montgomery's task group. Eighteen aircraft joined battle with American fighters and lost half their number. A smaller group of nine Japanese dive bombers of this force evaded U.S. aircraft and attacked Wasp and Bunker Hill but scored no hits; eight were shot down.
Weak central coherence theory hypothesizes that a limited ability to see the big picture underlies the central disturbance in autism. One strength of this theory is predicting special talents and peaks in performance in autistic people. Another theory, enhanced perceptual functioning, focuses more on the superiority of locally oriented and perceptual operations in autistic individuals. Yet another theory, monotropism, posits that autism stems from a different cognitive style, tending to focus attention and processing resources intensely, to the exclusion of other stimuli. These theories map well from the underconnectivity theory of autism.
In 2002, Israel Prize In 2005, Louisa Gross Horwitz Prize In 2006, Wolf Prize in Chemistry along with George Feher. In 2006, The EMET Prize for Art, Science and Culture in Life Sciences, along with Professor Peretz Lavie (Medicine) and Professor Eli Keshet (Biology) In 2007, Paul Ehrlich and Ludwig Darmstaedter Prize along with Harry Noller In 2008, the Albert Einstein World Award of Science for her pioneering contributions to protein biosynthesis in the field of ribosomal crystallography and her introduction of innovative techniques in cryo bio-crystallography. In 2009, the Nobel Prize in Chemistry (co-recipient with Thomas Steitz and Venkatraman Ramakrishnan). She was the first Israeli woman to be awarded a Nobel Prize. In 2010, Wilhelm Exner Medal In 2011, Marie Curie Medal awarded by the Polish Chemical Society In 2013 she became a member of the German Academy of Sciences Leopoldina. In 2015, she was awarded Honorary Doctorates from the University of Southern California, the De La Salle University, Manila/Philippines; the Joseph Fourier University, Grenoble/France; the Medical University of Lodz, Lodz/Poland; and the University of Warwick, UK. In 2018, Elizabeth Cabezas, President of the Ecuadorian National Assembly, presented Yonath with the Presea "Asamblea Nacional de la República del Ecuador, Dra. Matilde Hidalgo de Procel" (National Assembly of Ecuador Dr. Matilde Hidalgo de Procel Medal) for scientific merit.
Sources: en.wikipedia.org
The measure was criticized by governor Leite, who alerted that there was an imminent shortage of sedatives for the ICUs in the capital and the moment called for people to stay indoors to avoid the spread of the virus. The state Public Ministry (MP-RS) brought forth a public civil lawsuit with the Justice against the decree, which was suspended the day after. The municipal government attempted to reimplement the decree, but the State Court of Justice maintained the suspension. The attorney general of the Public Ministry, Fabiano Dallazen, also announced that there would be an investigation into Melo's criminal responsibility and that his attitudes as mayor only generated more insecurity in the population.
Komagataella, as mentioned above, is a methylotroph, meaning that it can grow with the simple methanol, as the only source of energy — Komagataella can grow fast in cell suspension with reasonably strong methanol solution, which would kill most other micro-organisms. In this case, the expression system is cheap to set up and maintain. Komagataella can grow up to a very high cell density. Under ideal conditions, it can multiply to the point where the cell suspension is practically a paste. As the protein yield from expression system in a microbe is roughly equal to the product of the proteins produced per cell, which makes Komagataella of great use when trying to produce large quantities of protein without expensive equipment. Comparing to other expression systems, such as S2-cells from Drosophila melanogaster and Chinese hamster ovary cells, Komagataella usually gives much better yields. Generally, cell lines from multicellular organisms require complex and expensive types of media, including amino acids, vitamins, as well as other growth factors. These types of media significantly increase the cost of producing heterologous proteins. Additionally, Komagataella can grow in media containing only one carbon source and one nitrogen source, which is suitable for isotopic labelling applications, like protein NMR.
A familial form of pseudohyperkalemia, a benign condition characterised by increased serum potassium in whole blood stored at cold temperatures, also exists. This is due to increased potassium permeability in red blood cells.
== Signs and symptoms == In gynecomastia, there is always enlargement of one or both breasts, symmetrically or asymmetrically, in a man. A soft, compressible, and mobile mass of breast tissue is felt under the nipple and its surrounding skin in contrast to softer fatty tissue, which is not associated with a mass. It may also be accompanied by breast tenderness or nipple sensitivity, which is commonly associated with gynecomastia observed in adolescents, typically early in development. Gynecomastia that is painful, bothersome, rapidly-growing, associated with masses in other areas of the body, or persistent should be evaluated by a clinician for potential causes. Dimpling of the skin, nipple discharge, and nipple retraction are not typical features of gynecomastia and may be associated with other disorders. Milky discharge from the nipple is not a typical finding, but may be seen in a gynecomastic individual with a prolactin secreting tumor. An increase in the diameter of the areola and asymmetry of the chest are other possible signs of gynecomastia. Much of the research on gynecomastia has focused on its causes and treatment, but little has explored its effects on mental health and overall quality of life. Gynecomastia has psychosocial implications that may be particularly challenging for adolescents who are experiencing physical maturation and self-identity formation, which includes body image disturbances, negative attitudes towards eating, self-esteem problems, social withdrawal, anxiety, and shame.
Although SJS can be caused by viral infections and malignancies, the main cause is medications. A leading cause appears to be the use of antibiotics, particularly sulfa drugs. Between 100 and 200 different drugs may be associated with SJS. No reliable test exists to establish a link between a particular drug and SJS for an individual case. Determining what drug is the cause is based on the time interval between first use of the drug and the beginning of the skin reaction. Drugs discontinued more than 1 month prior to onset of mucocutaneous physical findings are highly unlikely to cause SJS and TEN. SJS and TEN most often begin between 4 and 28 days after culprit drug administration. A published algorithm (ALDEN) to assess drug causality gives structured assistance in identifying the responsible medication. SJS may be caused by the medications rivaroxaban, vancomycin, allopurinol, valproate, levofloxacin, diclofenac, etravirine, isotretinoin, fluconazole, valdecoxib, sitagliptin, oseltamivir, penicillins, barbiturates, sulfonamides, phenytoin, azithromycin, oxcarbazepine, zonisamide, modafinil, lamotrigine, nevirapine, pyrimethamine, ibuprofen, ethosuximide, carbamazepine, bupropion, telaprevir, furosemide, and nystatin. Genetic susceptibility plays a significant role in drug-induced Stevens–Johnson syndrome. Individuals who carry HLA-B15:02 or HLA-A31:01 are at substantially increased risk of carbamazepine-induced Stevens–Johnson syndrome.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.